Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [5] - The company is currently advancing its lead drug candidate, Namodenoson, which is being evaluated in multiple clinical trials for liver and other cancers [5] Clinical Development - Namodenoson has shown promising results in treating decompensated liver cirrhosis, with a patient experiencing significant symptom improvement after 20 months of treatment [2][3] - The treatment led to the disappearance of episodes of decompensated liver cirrhosis and improvements in liver stiffness and elevated globulin levels, markers of advanced liver disease [2][3] Market Potential - The U.S. market for liver cirrhosis treatment is projected to grow to approximately $15 billion by 2030, highlighting the urgent need for effective therapies [3] - In 2017, an estimated 10.6 million people globally were affected by decompensated cirrhosis, indicating a significant patient population in need of treatment options [3] Drug Profile - Namodenoson is an orally bioavailable drug that selectively binds to the A3 adenosine receptor, which is highly expressed in diseased cells, contributing to its favorable safety profile [4] - The drug has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for hepatocellular carcinoma by the FDA [5]